Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

CymaBay Therapeutics’ shares shoot up on phase 2 data for liver drug

Monday, July 17, 2017 7:41
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Shares in CymaBay Therapeutics Inc (NASDAQ:CBAY) rose over 25% to $7.08 on Monday on positive phase 2 trial results.

The results were from the ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a life-threatening and life-limiting chronic cholestatic liver disease.

Seladelpar is in development for the treatment of liver diseases PBC and Nonalcoholic steatohepatitis (NASH).

After sharing preliminary results from this study, the FDA has agreed to allow continuation of seladelpar treatment beyond six months for the 5 mg and 10 mg doses, the group revealed.

“The data emerging from this study are impressive and support our hypothesis that lower doses of seladelpar than previously studied retain strong efficacy without raising a concern with transaminase elevations,” said Professor Gideon Hirschfield, Centre for Liver Research at the University of Birmingham, UK

“We also see that seladelpar activity is not associated with drug-induced itch, an important benefit for patients with PBC. If these results are maintained over longer periods, we think that seladelpar could offer patients significant advantages over existing treatments,” he added.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/181002/cymabay-therapeutics-shares-shoot-up-on-phase-2-data-for-liver-drug

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.